Oct. 23, 2013
/PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 3,250,000 shares of its common stock at a price to the public of
per share. The gross proceeds from this offering to Mirati are expected to be approximately
, before deducting underwriting discounts and commissions and other offering expenses payable by Mirati. Mirati has granted the underwriters a 30-day option to purchase up to an aggregate of 487,500 additional shares of common stock. The offering is expected to close on or about
October 29, 2013
, subject to customary closing conditions. Mirati expects to use net proceeds of this offering for research and development expenses, working capital, potential future licensing or partnership transactions and for other general corporate expenses.
Jefferies LLC and Leerink Swann LLC are acting as joint book-running managers in the offering and
& Co. is acting as lead manager in the offering.
Registration statements relating to the shares to be sold in the offering have been filed with the Securities and Exchange Commission ("SEC") and became effective on
October 23, 2013
. The registration statements, including the prospectus relating to the offering, is available on the SEC's website at
. Copies of the prospectus may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor,
New York, NY
10022, or by telephone at (877) 547-6340, or by e-mail at
or from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor,
02110, or by telephone at (800) 808-7525, or by e-mail at
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the shares in any state or other jurisdiction which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.